Description
IRESSA (Gefitinib) is a chemotherapy medication that can be prescribed to treat a certain type of lung cancer. IRESSA is approved to treat metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Directions
The normal IRESSA dosage is 250 mg once daily until the disease becomes worse or the side effects of the drug are not tolerable.
Take IRESSA exactly as prescribed by the oncologist.
Do not take a missed dose if the next scheduled dose is 12 hours or less away.
Ingredients
The active ingredient in IRESSA is gefitinib.
Gefitinib is a tyrosine kinase inhibitor (TKI) that blocks the activity of a cell receptor called an epidermal growth factor receptor (EGFR). EGFR contributes to the overactive replication of cancer cells, and by blocking its activity, IRESSA prevents the growth of some cancerous cells.
Fact Table |
Formula |
C22H24ClFN4O3 |
License |
AU, EU EMA, US FDA |
Bioavailability |
59% |
Legal status |
RX Only |
Chemical Name |
Gefitinib |
Elimination half-life |
6-49 hours |
Dosage (Strength) |
250mg (30 tablets) |
Pregnancy |
Consult a doctor |
Brands |
Iressa |
Protein binding |
90% |
PubChem CID |
123631 |
MedlinePlus |
a607002 |
ChEBI |
49668 |
ATC code |
L01EB01 |
DrugBank |
DB00317 |
KEGG |
D01977 |
Routes of administration |
Oral |
Interactions
IRESSA can interact with many other medications. Some examples include:
- Abametapir
- Antacids
- Conivaptan
- Dabrafenib
- Enzalutamide
- Idelalisib
- Itraconazole
- Mifepristone
- Rifampicin
- Warfarin
Cautions
IRESSA (Gefitinib) is for oncology use only. It can only be used under the close supervision of an oncologist.
IRESSA is a chemotherapeutic agent and has many different side effects and toxicities. Your oncologist should monitor you for the following:
- Dermatological (skin) toxicity
- Gastrointestinal toxicity
- Ocular (eye) toxicity
- Pulmonary (lung) toxicity
Side Effects
IRESSA has many potential side effects. Your oncologist will review these with you before prescribing it. Some of the common ones include:
- Anorexia
- Decreased appetite
- Diarrhea
- Fatigue
- Increased liver enzymes
- Insomnia
- Nausea
- Paronychia
- Proteinuria
- Pruritus
- Rash
- Skin reactors
- Vomiting
- Weakness
- Xeroderma
Buy IRESSA online with a valid prescription from your healthcare provider. IRESSA is a hazardous medication, so ensure that your doctor knows your plan for obtaining IRESSA online. Purchasing online may be a lower IRESSA price.
References
- Inspra [package insert].New York, NY: Pfizer; 2002.
Frequently Asked Questions about Iressa (Gefitinib)
What is Iressa (Gefitinib)?
Iressa, with the generic name Gefitinib, is a medication used to treat certain types of cancer. It belongs to a class of drugs known as EGFR inhibitors, which work by interfering with the growth and spread of cancer cells in the body.
What types of cancer is Iressa used to treat?
Iressa is primarily used for the treatment of non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It may also be used for certain breast and other cancers.
How does Iressa work?
Iressa works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which is a protein involved in the signaling pathways that lead to cancer cell proliferation.
How is Iressa administered?
Iressa is administered orally. It's crucial to follow the dosing instructions provided by the healthcare provider.
What are the side effects of Iressa?
Common side effects may include diarrhea, skin rash, and other symptoms. It is important to consult with a healthcare provider to understand the full range of possible side effects and to receive guidance on managing them.
Are there any specific gene mutations that Iressa targets?
Iressa is particularly effective in treating patients whose tumors have specific mutations in the EGFR gene, namely exon 19 deletions or exon 21 (L858R) substitution mutations.
Is Iressa a first-line treatment for NSCLC?
Yes, Iressa is used as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors exhibit certain EGFR gene mutations.
Is Iressa being studied for the treatment of other types of cancer?
Yes, besides its approved use for NSCLC, Gefitinib is also being studied for its potential in treating other types of cancers.
Where can I find more information about Iressa?
Detailed information about Iressa can be obtained from healthcare providers, the FDA, or the manufacturer, AstraZeneca.
How can I report adverse reactions or quality issues with Iressa?
Adverse reactions or quality issues can be reported to the FDA's MedWatch Adverse Event Reporting program or to the manufacturer, AstraZeneca.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 5477